UK Markets close in 5 hrs 50 mins

Celyad SA (CYAD)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
4.4600-0.2600 (-5.51%)
At close: 4:00PM EDT
4.5000 +0.04 (+0.90%)
Pre-market: 04:07AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close4.7200
Open4.5000
Bid0.0000 x 3000
Ask0.0000 x 900
Day's range4.2900 - 4.7000
52-week range3.7600 - 10.3100
Volume33,706
Avg. volume23,239
Market cap68.947M
Beta (5Y monthly)1.49
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • Globe Newswire

    Celyad Oncology to Present New Data on Allogeneic CAR T Therapy Program at the Society for Immunotherapy of Cancer Annual Meeting

    Conference to take place both in-person in Washington D.C. and virtually November 10-14, 2021MONT-SAINT-GUIBERT, Belgium, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that three abstracts about the Company’s allogeneic CAR T therapy programs will be presented at the Society for Immunotherapy of Cancer

  • Globe Newswire

    Celyad Oncology Announces September 2021 Conferences Schedule

    MONT-SAINT-GUIBERT, Belgium, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company plans to participate at the following conferences in September 2021: 2021 Wells Fargo Virtual Healthcare ConferenceDates: Thursday, September 9 – Friday, September 10, 2021Presentation date: Thursday, September

  • Globe Newswire

    Celyad Oncology Reports First Half 2021 Financial Results and Recent Business Highlights

    •Enrollment continues at dose level three in Phase 1 IMMUNICY-1 trial evaluating CYAD-211 in relapsed/refractory multiple myeloma (r/r MM); next clinical update expected by year-end 2021 •Phase 1b KEYNOTE-B79 trial set to evaluate CYAD-101 with KEYTRUDA® in metastatic colorectal cancer (mCRC) patients with microsatellite stable disease on-track to begin in the fourth quarter of 2021 •IND-enabling studies in progress for first-in-class shRNA-based allogeneic, IL-18-armored CAR T candidate CYAD-20